REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.

Slides:



Advertisements
Similar presentations
AKI in Pediatrics Patrick D. Brophy MD Associate Professor
Advertisements

IRMA TRUpoint Creatinine Cartridge Field Launch
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Mechanisms and Management in Acute Kidney Injury Paul Stevens Kent Kidney Care Centre.
Journal Club Rakesh Latchamsetty October 5, 2007.
Renal Megan McClintock, RN, MS 10/27/11 “TO PEE IS TO LIVE”
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
Myeloma and Renal Disease
PLC’s Growth Initiative: Renal Guard May 7, 2007.
3. The ASCERTAIN Study. Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor.
Sodium Bicarbonate for the Prevention of Contrast Induced Nephropathy: A Meta-analysis of Published Clinical Trials Vijayalakshmi Kunadian 1,2, Azfar Zaman.
Acute Kidney Injury. 49 year old man was a single vehicle MVC in which he was ejected. His injuries include: 49 year old man was a single vehicle MVC.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
REMEDIAL II REnal Insufficiency Following Contrast MEDIA Administration II TriaL RenalGuard system in high risk patients for contrast induced acute kidney.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
4/9/08 Urinary System Chapter 24 – Day 4. 4/9/08 Renal Failure  Decrease or increase in normal renal function  Acute & Chronic – discussed in next few.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Bicarbonate-Based Solutions in the Management of Acute Kidney Injury Vania Cecilia Prudencio-Ribera, MD 1 ; Universidad Mayor de San Simón, School of Medicine,
Conclusions. Conclusions -In patients undergoing primary angioplasty, prophylactic treatment with N-acetylcysteine seems to reduce the rate of contrast-medium.
Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.
Prevention of Serious Adverse Outcomes Following Angiography (PRESERVE) Trial Steven D. Weisbord MD, MSc.
Acetylcysteine for the prevention of Contrast- induced nephropaThy (ACT) Trial: The ACT Trial Investigators Presenter: Otavio Berwanger (MD; PhD) Chair.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
A.Rasoolzadeh MD. Contrast induced nephropathy (CIN): A kind of reversible AKI as a rise in serum creatinine (by 25%) during of h after receipt.
Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.
Risk prediction models of AKI DR.F.Haghverdi MD Outline AKI epidemiology and definition(brenner2016) Biomarkers Risk prediction models of AKI (post CABG,
Clinical Outcomes with Newer Antihyperglycemic Agents
TAVR in Patients With Chronic Kidney Disease
Clinical Outcomes with Newer Antihyperglycemic Agents
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Early high-dose Rosuvastatin for
Volume 62, Issue 6, Pages (December 2002)
Contrast Awareness: Why and When Do we Worry?
HOPE: Heart Outcomes Prevention Evaluation study
Clinical Research at the VA
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
VA Cooperative Studies Program Trial # 578
Scandinavian Simvastatin Survival Study (4S)
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II)Clinical Perspective by Carlo Briguori, Gabriella Visconti, Amelia Focaccio,
Valsartan in Acute Myocardial Infarction Trial Investigators
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Hexabrix Key Clinical Review Mehran, 2009
Nat. Rev. Nephrol. doi: /nrneph
Pearls Presentation Use of N-Acetylcysteine For prophylaxis of Radiocontrast Nephrotoxicity.
Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional.
Figure 2 Milestones in paediatric acute kidney injury (AKI) research
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
BACKGROUND The optimal timing of RRT initiation in critically ill patients with AKI is still uncertain No consensus to guide clinical practice of acute.
Management of Acute Kidney Injury: Core Curriculum 2018
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
Section 4: Contrast-induced AKI
End point Fenoldopam, n (%) Dopamine, n (%) p
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volatile anesthetics in preventing acute kidney injury after cardiac surgery: A systematic review and meta-analysis  Jieru Cai, MD, Rende Xu, MD, PhD,
Ezetimibe/simvastatin
Volume 62, Issue 6, Pages (December 2002)
TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)
Section 4: Contrast-induced AKI
Diagnostic criteria for AKI
Interventional Cardiology Mediterranea Cardiocentro, Naples, Italy
Presentation transcript:

REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced Acute Kidney Injury Hypothesis The RenalGuard™ System is superior to prophylaxis with sodium bicarbonate infusion plus NAC in preventing CI-AKI in high and very high risk patients. The RenalGuard™ System A real-time measurement and real-time matched fluid replacement device designed to accommodate RenalGuard™ therapy RenalGuard™ Therapy The theory that creating and maintaining a high urine output is beneficial by allowing a quick elimination of contrast media, thereby reducing its toxic effects.

REMEDIAL II Study Design Randomized, multicenter, investigator-sponsored Primary Endpoint The rate of contrast induced acute kidney injury (CI-AKI), defined as an increase of ≥0.3 mg/dL in serum creatinine (sCr) concentration 48 hours after the procedure

Secondary Endpoints Increase in sCr conentration ≥25% and ≥0.5 mg/dL at 48 hours post contrast exposure Changes in serum cystatin concentration at 24 and 48 hours post contrast exposure Rate of acute renal failure requiring dialysis Rate of in-hospital and 1-month major adverse events REMEDIAL II